DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability

Yunshu Shi,Junyong Wang,Qiang Yuan,Yingying Chen,Miao Zhao,Xiaoyu Li,Zitong Wang,Hao Zhou,Fangli Zhu,Bing Wei,Yanan Jiang,Jimin Zhao,Yan Qiao,Zigang Dong,Kangdong Liu
DOI: https://doi.org/10.1038/s41388-024-03162-6
IF: 8.756
Oncogene
Abstract:Novel therapeutic targets and their inhibitors for esophageal squamous cell carcinoma (ESCC) prevention and therapy are urgently needed. This study aimed to investigate the function of DEAD-box helicase 5 (DDX5) in ESCC progression and to identify a promising inhibitor of DDX5. We verified that DDX5 was highly expressed in ESCC and played an oncogenic role, binding with vav guanine nucleotide exchange factor 3 (VAV3) mRNA and facilitating VAV3 mRNA N6-methyladenosine (m6A) modification by interacting with the m6A methyltransferase 3 (METTL3). M6A-modified VAV3 mRNA was identified by insulin-like growth factor 1 (IGF2BP1), increasing mRNA stability. Methylnissolin-3-β-D-O-glucoside (MD) inhibited ESCC progression through the DDX5-VAV3 axis. Our findings suggest that DDX5 promotes ESCC progression. MD inhibits ESCC progression by targeting DDX5.
What problem does this paper attempt to address?